Press Release

Agenus Presents Posters on Checkpoint Antibody Product Candidates at the American Association for Cancer Research (AACR) 2016 Annual Meeting

April 18, 2016

LEXINGTON, Mass.--()--Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company developing checkpoint modulator antibodies and cancer vaccines, today announced that three abstracts on the Company's checkpoint modulator product candidates were accepted for poster presentations at the American Association for Cancer Research (AACR) 2016 Annual Meeting. The conference is taking place in New Orleans from April 16-20, 2016.

Poster Details:

  • OX40
    Poster Title: INCAGN01949: A Novel Anti-OX40 Agonist Antibody with the Potential to Enhance Tumor Specific T-cell Responsiveness, while Selectively Depleting Intratumoral Regulatory T Cells
    Poster Number: #3204
    Session Date: Tuesday, April 19, 2016
    Session Time: 8:00 AM -12:00 PM CDT
  • GITR
    Poster Title: A Novel Agonist Antibody (INCAGN01876) that Targets the Costimulatory Receptor GITR
    Poster Number: #3220
    Session Date: Tuesday, April 19, 2016
    Session Time: 8:00 AM -12:00 PM CDT
  • CTLA-4
    Poster Title: AGEN1884 and AGEN2041: Two Functionally Distinct Anti-CTLA-4 Antagonist Antibodies
    Poster Number: #5005
    Session Date: Wednesday, April 20, 2016
    Session Time: 7:30 AM -11:00 AM CDT

Agenus is partnered with Incyte Corporation for the development of INCAGN1949 and INCAGN1876, and is partnered with Recepta Biopharma SA for certain South American rights for AGEN1884 and AGEN2041. Abstracts and posters will become available on the Company’s website at following the poster sessions.

About Agenus

Agenus is an immuno-oncology company focused on the discovery and development of revolutionary new treatments that engage the body’s immune system to benefit patients suffering from cancer. By combining multiple powerful platforms, Agenus has established a highly integrated approach to target identification and validation, and for the discovery, development and manufacturing of monoclonal antibodies that modulate targets of interest. The company’s broad portfolio of novel checkpoint modulator and other immuno-modulatory monoclonal antibodies, vaccines and adjuvants work in combination to provide the opportunity to create best-in-class therapeutic regimens. Agenus’ heat shock protein-based vaccine, Prophage™, has successfully completed Phase 2 studies in newly-diagnosed glioblastoma. The company is collaborating with Merck and Incyte to discover and develop multiple checkpoint modulators. For more information, please visit; information that may be important to investors will be routinely posted on our website.

Forward-Looking Statements

This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including statements regarding the Company’s upcoming presentations. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include, among others, the factors described under the Risk Factors section of Agenus’ Form 10-K filed with the Securities and Exchange Commission on March 15, 2016. Agenus cautions investors not to place considerable reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this press release, and Agenus undertakes no obligation to update or revise the statements, other than to the extent required by law. All forward-looking statements are expressly qualified in their entirety by this cautionary statement.



Agenus Inc.
Michelle Linn, 774-696-3803
Agenus Inc.
BMC Communications
Brad Miles, 646-513-3125